An interventional study of vonoprazan, amoxicillin, tripotassium dicitrate bismuthate and vonoprazan, amoxicillin in Helicobacter Pylori Eradication, sponsored by Kaohsiung Medical University. Recruiting at 1 site in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-15.
Sponsored by Kaohsiung Medical University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
For this multi-center, randomized, open-label, superiority trial, we will recruit 780 adult patients with H. pylori infection from ten medical centers or regional hospitals in Taiwan. Using a computer generated randomized sequence, we randomly allocate patients (1:1:1; block size of six) to either 14-day bismuth-amoxicillin-vonoprazan triple therapy, 14-day vonoprazan dual therapy, or 14-day rabeprazole-triple therapy. Patients are asked to return at the second week to assess drug adherence and adverse events. Post-treatment H. pylori status is assessed by 13C-urea breath test at week 6. Participants with failure of H. pylori eradication will randomly receive either 14-day vonoprazan-based or 14-day esomeprazole-based bismuth quadruple therapy. Finally, the rates of eradication and adverse events will be compared between groups by chi-square test. Additionally, the effects of antibiotic resistances of H. pylori as well as CYP3A4, CYP2C19 and IL-1B -511 genotypes of host on the eradication efficacies of above first-line and second-line anti-H. pylori treatments are assessed by multivariate analysis.
Kaohsiung Medical University is the lead sponsor of 56 studies on the registry; 17 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
(1) At least 18 years old. (2) Subjects infected with Helicobacter pylori.
Exclusion Criteria:
vonoprazan 20mg twice a day + amoxicillin 750mg four times a day + tripotassium dicitrate bismuthate 300mg four times a day
Drug: vonoprazan, amoxicillin, tripotassium dicitrate bismuthate
vonoprazan 20mg twice a day + amoxicillin 750mg,Four times a day
Drug: vonoprazan, amoxicillin
rabeprazole 20mg twice a day + amoxicillin 1gm twice a day + clarithromycin 500mg twice a day
Drug: rabeprazole, amoxicillin, clarithromycin
bismuth-amoxicillin-vonoprazan triple therapy
Drug pages: VonoprazanStudies of VonoprazanVonoprazan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · AmoxicillinStudies of AmoxicillinAmoxicillin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
vonoprazan-amoxicillin dual therapy
Drug pages: RabeprazoleStudies of RabeprazoleRabeprazole pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · AmoxicillinStudies of AmoxicillinAmoxicillin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · ClarithromycinStudies of ClarithromycinClarithromycin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
proton pump inhibitor-based standard triple therapy
the eradication rate of Helicobacter pylori
evalute eradication outcome by 13C urea breath test
Time frame: 8 week after finishing study drugs
genotype analysis
CYP3A4, CYP2C19 and IL-1B -511 genotypes
Time frame: 1 day
Started Nov 2023 (actual). Primary completion is estimated for Dec 2026, 37 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Vonoprazan · Amoxicillin
Kaohsiung Medical University